Ranibizumab for neovascular age-related macular degeneration.

Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology (2012) 11.91

Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature (2008) 7.10

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med (2015) 7.08

Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis (2012) 4.42

Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 3.85

Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat Med (2008) 3.67

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology (2007) 3.49

Molecular pathology of age-related macular degeneration. Prog Retin Eye Res (2008) 3.35

Age-related macular degeneration. Lancet (2008) 3.34

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care (2010) 3.29

Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol (2007) 3.08

Comparison of natamycin and voriconazole for the treatment of fungal keratitis. Arch Ophthalmol (2010) 2.98

Vascular endothelial growth factor in eye disease. Prog Retin Eye Res (2008) 2.73

Mechanisms of age-related macular degeneration. Neuron (2012) 2.62

Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye (Lond) (2012) 2.52

CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature (2009) 2.39

Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol (2010) 2.32

One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Am J Ophthalmol (2014) 2.24

Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP). Graefes Arch Clin Exp Ophthalmol (2009) 2.19

Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology (2012) 2.19

Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nat Rev Drug Discov (2010) 2.14

Immunology of age-related macular degeneration. Nat Rev Immunol (2013) 2.14

The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med (2006) 2.12

Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23~27~24 clusters. Proc Natl Acad Sci U S A (2011) 2.10

Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis). Trans Am Ophthalmol Soc (2009) 2.09

Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol (2011) 2.07

Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol (2009) 2.06

Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond) (2011) 2.05

A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2010) 2.04

Bimonthly injections of ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2014) 2.04

Intravitreal ranibizumab in retinal macroaneurysm. Graefes Arch Clin Exp Ophthalmol (2010) 1.97

Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol (2013) 1.97

Vascular endothelial growth factors and vascular permeability. Cardiovasc Res (2010) 1.89

MicroRNAs regulate ocular neovascularization. Mol Ther (2008) 1.89

A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2008) 1.89

Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol (2007) 1.88

Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest (2012) 1.79

Fibrosis and diseases of the eye. J Clin Invest (2007) 1.79

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev (2014) 1.76

Statin use and the five-year incidence and progression of age-related macular degeneration. Am J Ophthalmol (2007) 1.73

Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2012) 1.70

Drusen characterization with multimodal imaging. Retina (2010) 1.70

New treatments for neovascular acute macular degeneration. BMJ (2007) 1.69

Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina (2009) 1.67

Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med (2012) 1.66

Ocular neovascularization. J Mol Med (Berl) (2013) 1.65

Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women. Ophthalmology (2009) 1.62

Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response. Br J Ophthalmol (2013) 1.61

Stem cells in retinal regeneration: past, present and future. Development (2013) 1.59

Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2009) 1.57

Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 1.57

North Carolina Macular Dystrophy Is Caused by Dysregulation of the Retinal Transcription Factor PRDM13. Ophthalmology (2015) 1.55

Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol (2007) 1.55

[Incidence of endophthalmitis after intravitreal Avastin injection with and without postoperative topical antibiotic application]. Ophthalmologe (2007) 1.53

Functional cone rescue by RdCVF protein in a dominant model of retinitis pigmentosa. Mol Ther (2009) 1.53

Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov (2012) 1.52

Current update on retinopathy of prematurity: screening and treatment. Curr Opin Pediatr (2011) 1.50

Computer-aided quantification of retinal neovascularization. Angiogenesis (2009) 1.50

Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye (Lond) (2013) 1.49

Colour photographs for screening in neovascular age-related macular degeneration: are they necessary? Eye (Lond) (2011) 1.47

The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc (2012) 1.46

Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis. BMJ (2007) 1.46

Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2014) 1.45

Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med (2010) 1.45

Three-dimensional segmentation of fluid-associated abnormalities in retinal OCT: probability constrained graph-search-graph-cut. IEEE Trans Med Imaging (2012) 1.44

Surgical treatment of peripapillary choroidal neovascularisation. Br J Ophthalmol (2007) 1.44

A hypoxia-responsive glial cell-specific gene therapy vector for targeting retinal neovascularization. Invest Ophthalmol Vis Sci (2014) 1.43

Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol (2014) 1.42

Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes. Clin Ophthalmol (2016) 1.42

Complement, age-related macular degeneration and a vision of the future. Arch Ophthalmol (2010) 1.42

Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol (2014) 1.41

Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol (2014) 1.41

Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. PLoS One (2015) 1.40

Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol (2006) 1.39

Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J Clin Invest (2008) 1.39

Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol (2008) 1.38

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One (2012) 1.38

Axl is essential for VEGF-A-dependent activation of PI3K/Akt. EMBO J (2012) 1.38

Persisent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol (2008) 1.37

Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy. Eye (Lond) (2016) 1.37

Ocular associations of diabetes other than diabetic retinopathy. Diabetes Care (2008) 1.35

Ultrahigh-speed swept-source OCT angiography in exudative AMD. Ophthalmic Surg Lasers Imaging Retina (2014) 1.35

CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS One (2009) 1.34

Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2010) 1.34

Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci (2008) 1.33

Attenuated glial reactions and photoreceptor degeneration after retinal detachment in mice deficient in glial fibrillary acidic protein and vimentin. Invest Ophthalmol Vis Sci (2007) 1.33

Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization. FASEB J (2010) 1.31

A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye (Lond) (2014) 1.30

Imaging of the retinal pigment epithelium in age-related macular degeneration using polarization-sensitive optical coherence tomography. Invest Ophthalmol Vis Sci (2009) 1.30

Oxidative stress promotes ocular neovascularization. J Cell Physiol (2009) 1.28

Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD. Graefes Arch Clin Exp Ophthalmol (2014) 1.28

Mitochondrial DNA damage as a potential mechanism for age-related macular degeneration. Invest Ophthalmol Vis Sci (2010) 1.28

Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther (2010) 1.27

Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology (2013) 1.26

Screening and Treatment in Retinopathy of Prematurity. Dtsch Arztebl Int (2015) 1.26

Age-related macular degeneration: genetic and environmental factors of disease. Mol Interv (2010) 1.24

Long-term safety and efficacy of human-induced pluripotent stem cell (iPS) grafts in a preclinical model of retinitis pigmentosa. Mol Med (2012) 1.24

Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov (2010) 1.24

Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med (2006) 20.84

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology (2012) 8.29

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology (2009) 6.44

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology (2012) 6.35

Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology (2006) 5.79

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol (2008) 5.22

Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol (2003) 4.78

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology (2010) 4.09

Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology (2013) 3.92

A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology (2009) 3.76

Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology (2007) 3.11

Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol (2007) 3.00

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology (2013) 2.99

Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology (2011) 2.78

Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina (2008) 2.72

Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis. Retina (2013) 2.49

Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology (2007) 2.41

The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology (2013) 2.35

Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology (2012) 2.32

Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol (2012) 2.30

Oxidative stress and calcium signaling in the adverse effects of environmental particles (PM10). Free Radic Biol Med (2003) 2.28

Evaluation of wound closure in oblique 23-gauge sutureless sclerotomies with visante optical coherence tomography. Am J Ophthalmol (2008) 2.26

Cosmetic facial fillers and severe vision loss. JAMA Ophthalmol (2014) 2.20

One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology (2012) 2.20

Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol (2004) 2.18

A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology (2006) 2.17

Utility of intraoperative optical coherence tomography during vitrectomy surgery for vitreomacular traction syndrome. Retina (2014) 2.15

Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol (2013) 2.14

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology (2013) 2.13

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol (2006) 2.04

Inspiratory loading intensity does not influence lactate clearance during recovery. Med Sci Sports Exerc (2012) 2.00

Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol (2005) 1.99

Intrasurgical dynamics of macular hole surgery: an assessment of surgery-induced ultrastructural alterations with intraoperative optical coherence tomography. Retina (2014) 1.97

Novel microarchitectural dynamics in rhegmatogenous retinal detachments identified with intraoperative optical coherence tomography. Retina (2013) 1.96

Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology (2012) 1.95

Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center. Medicine (Baltimore) (2003) 1.94

Optical coherence tomography enhanced depth imaging of choroidal tumors. Am J Ophthalmol (2011) 1.91

Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol (2007) 1.89

Short-term outcomes of 23-gauge pars plana vitrectomy. Am J Ophthalmol (2008) 1.89

Absence of branches from xylan in Arabidopsis gux mutants reveals potential for simplification of lignocellulosic biomass. Proc Natl Acad Sci U S A (2010) 1.88

Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome. Br J Ophthalmol (2013) 1.86

Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology (2009) 1.86

The role of free radicals in the toxic and inflammatory effects of four different ultrafine particle types. Inhal Toxicol (2003) 1.83

Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology (2011) 1.79

Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am J Ophthalmol (2003) 1.74

Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina (2007) 1.68

Panretinal photocoagulation for proliferative diabetic retinopathy: pattern scan laser versus argon laser. Am J Ophthalmol (2011) 1.62

Optical coherence tomography 3: Automatic delineation of the outer neural retinal boundary and its influence on retinal thickness measurements. Invest Ophthalmol Vis Sci (2004) 1.62

Optical coherence tomographic patterns of diabetic macular edema. Am J Ophthalmol (2006) 1.62

SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. Ophthalmic Surg Lasers Imaging Retina (2013) 1.60

Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology (2008) 1.60

Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab. Ophthalmology (2009) 1.52

Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology (2013) 1.52

The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line. Toxicol Appl Pharmacol (2008) 1.50

Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology (2012) 1.48

Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med (2013) 1.47

Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A (2011) 1.47

Adverse events after intravitreal triamcinolone in patients with and without uveitis. Ophthalmology (2007) 1.45

Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the "flying saucer" sign). Clin Ophthalmol (2010) 1.43

Prevalence of outer retinal tubulation after anti-VEGF therapy for age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina (2015) 1.42

Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging (2005) 1.38

Neovascular age-related macular degeneration: potential therapies. Drugs (2008) 1.38

Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology (2006) 1.37

The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology (2011) 1.34

Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. Retina (2010) 1.32

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol (2008) 1.31

Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol (2012) 1.31

Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol (2005) 1.26

IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk. Int J Radiat Oncol Biol Phys (2004) 1.26

Mitochondrial DNA haplogroups associated with age-related macular degeneration. Invest Ophthalmol Vis Sci (2009) 1.26

Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina (2012) 1.24

Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology (2012) 1.19

Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology (2011) 1.18

Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol (2008) 1.18

Implantable miniature telescope for the treatment of visual acuity loss resulting from end-stage age-related macular degeneration: 1-year results. Ophthalmology (2006) 1.17

Evaluation of choroidal thickness in retinitis pigmentosa using enhanced depth imaging optical coherence tomography. Br J Ophthalmol (2012) 1.17

A novel segmentation algorithm for volumetric analysis of macular hole boundaries identified with optical coherence tomography. Invest Ophthalmol Vis Sci (2013) 1.13

Verteporfin photodynamic therapy of six eyes with retinal capillary haemangioma. Acta Ophthalmol (2010) 1.12

A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology (2010) 1.10

Evaluating the uptake and intracellular fate of polystyrene nanoparticles by primary and hepatocyte cell lines in vitro. Toxicol Appl Pharmacol (2009) 1.09

Detection of new-onset choroidal neovascularization using optical coherence tomography: the AMD DOC Study. Ophthalmology (2012) 1.09

Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant. Am J Ophthalmol (2006) 1.09

Evolving strategies in the management of diabetic macular edema: clinical trials and current management. Can J Ophthalmol (2013) 1.08

An investigation into the potential for different surface-coated quantum dots to cause oxidative stress and affect macrophage cell signalling in vitro. Nanotoxicology (2010) 1.08

GUX1 and GUX2 glucuronyltransferases decorate distinct domains of glucuronoxylan with different substitution patterns. Plant J (2013) 1.06

Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology (2010) 1.06

Contrast-enhanced intraoperative optical coherence tomography. Br J Ophthalmol (2013) 1.06

Blast eye injuries: a review for first responders. Disaster Med Public Health Prep (2010) 1.06